Iverson Genetic Diagnostics Selects UPS to Provide Shipping Services for Medicare Approved WARFARIN Study Addressing Bleeding

BOTHELL, Wash.--(BUSINESS WIRE)--Iverson Genetic Diagnostics today announced the selection of UPS (NYSE:UPS) to provide shipping services for its upcoming WARFARIN Study. In late June of 2010, Iverson Genetic Diagnostics, Inc. received approval from the Centers for Medicare & Medicaid Services (CMS) to conduct a two-year study that will assess the impact of genetic information on the occurrence of adverse bleeding events when determining the initial dose of warfarin compared to adverse events for those not using genetics in dose determination. The randomized and blinded, multi-center study will involve more than 7,000 patients at over 50 hospital sites nationwide.